Lyka Labs approves ₹230.14 crore impairment, posts Q4 FY26 results, sets record date
Lyka Labs reported an impairment loss of ₹230.14 crore in its subsidiary, Lyka BDR. The company also announced its audited financial results for FY26. A record date of June 4, 2026, was set for share allotment under a merger scheme. The 47th AGM will be held on August 10, 2026.
The impairment of ₹230.14 crore is a substantial amount relative to the company's financial exposure in the subsidiary, directly affecting the company's reported financials and potentially investor confidence.
The significant impairment loss of ₹230.14 crore in the subsidiary's investment and loans indicates poor performance and financial distress in the subsidiary, negatively impacting the parent company's financial health.
Lyka Labs Limited announced the outcome of its Board Meeting held on May 25, 2026. The board approved the recognition of an impairment loss amounting to ₹2301.44 Lakhs (₹230.14 crore) in the value of investment and loans in its subsidiary, Lyka BDR International Limited. This impairment is due to continuous operational losses and eroding net worth of Lyka BDR. The company's financial exposure in Lyka BDR stands at ₹2301.44 Lakhs, comprising Equity Investment of ₹1469.05 Lakhs and Unsecured Loan of ₹832.39 Lakhs.
The board also considered and approved the audited financial results for the quarter and financial year ended March 31, 2026. The auditors, M/s. D. Kothary & Co., issued an unmodified opinion on these results.
Furthermore, Lyka Labs Limited fixed Thursday, June 04, 2026, as the Record Date for determining equity shareholders entitled to receive equity shares of the Transferee Company pursuant to a Scheme. As per the Scheme, 23 fully paid-up equity shares of the Transferee Company (face value ₹10 each) will be issued for every 100 fully paid-up equity shares of the Transferor Company held on the Record Date. These shares are proposed for listing on BSE and NSE, subject to regulatory approvals.
The 47th Annual General Meeting (AGM) of the Company is scheduled to be held on Monday, August 10, 2026, through a permission mode. The Board Meeting commenced at 1:00 pm and concluded at 3:20 pm.
What to do with a filing like this
Lyka Labs Limited filed this with the NSE as a statutory disclosure, categorised under other results related. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lyka Labs Limited. Read the original for the full detail.